Purpose: The purpose of the article was to determine the impact of Dual Registration (DR) image-guided radiotherapy (IGRT) on clinical judgement and treatment delivery for patients with oropharyngeal cancer before implementation.
Methods: Ninety cone beam computed tomography images from 10 retrospective patients were matched using standard clipbox registration (SCR) and DR. Three IGRT specialist radiographers performed all registrations and evaluated by intraclass correlation to determine inter-rater agreement, Bland-Altman with 95% limits of agreement to determine differences between SCR and DR procedures, changes in clinical judgment, time taken to perform registrations, and radiographer satisfaction.
Results: Inter-rater agreement between radiographers using both SCR and DR was high (0.867 and 0.917, P ≤ .0001). The 95% limits of agreement between SCR and DR procedures in the mediolateral, cranial-caudal, and ventrodorsal translational directions were -6.40 to +4.91, -7.49 to +6.05, and -7.00 to +5.44 mm, respectively. The mediolateral direction demonstrated significant proportional bias (P ≤ .001) suggesting non-agreement between SCR and DR. Eighty percent of DR matches resulted in a change in clinical judgement to ensure maximum target coverage. Mean registration times for SCR and DR were 94 and 115 seconds, respectively, and radiographers found DR feasible and satisfactory.
Conclusion: The standard method using SCR in patients with oropharyngeal cancer underestimates the deviation in the lower neck. In these patients, DR is an effective IGRT tool to ensure target coverage of the inferior neck nodes and has demonstrated acceptability to radiotherapy clinical practice.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jmir.2017.09.004 | DOI Listing |
Objective: This study aims to compare the effectiveness of 2 artificial saliva substitutes (Biotène vs HydraSmile) in the symptomatic management of radiation-induced xerostomia.
Study Design: Randomized double-blind cross-over study.
Setting: Single tertiary care academic institution.
Cureus
December 2024
Pathology, Prince Sultan Military Medical City, Riyadh, SAU.
We report an unusual case of a 39-year-old male patient with a previous history of treated classical Hodgkin lymphoma, presenting with tongue ulcer and left ear pain who was subsequently diagnosed with invasive squamous cell carcinoma of the oropharynx. This case highlights the importance of vigilance in patients with a history of lymphoma and the potential for the development of secondary malignancies. We discuss the clinical, radiological, and pathological findings and emphasize the need for close monitoring and early intervention in such cases.
View Article and Find Full Text PDFRep Pract Oncol Radiother
December 2024
Radiation Oncology, St Luke's Hospital, Network, Dublin, Ireland.
Background: The onset of the coronavirus disease 2019 (COVID-19) outbreak caused major interruptions to the entire healthcare network affecting referral, diagnosis and treatment pathways with the potential to affect cancer treatment outcomes. In Ireland a national lockdown was initiated in March 2020 involving a stay-at-home order with a limitation on travel, social interactions and closure of schools, universities and childcare facilities. We designed a retrospective study comparing treatment outcomes for patients with oropharyngeal cancer treated before and during the COVID pandemic.
View Article and Find Full Text PDFJ Orthod Sci
November 2024
Assistant Professor, SRM Dental College, Bharathi Salai, SRM Institute of Science and Technology, Chennai, Tamil Nadu, India.
Background And Objective: Skeletal Class II malocclusion patients frequently exhibit an extended craniocervical position. The study's objective was to evaluate how the craniocervical posture has changed following skeletal class II correction using the Forsus fatigue-resistant device (FFRD).
Methodology: A retrospective analysis was undertaken using the pre- and post-treatment records of 35 skeletal class II patients who used the FFRD to achieve class II correction.
Lancet Respir Med
December 2024
Population Policy and Practice Department, UCL Great Ormond Street Institute of Child Health, University College London, London, UK; Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK. Electronic address:
Background: In phase 2 trials in people with cystic fibrosis aged 18 years and older, vanzacaftor-tezacaftor-deutivacaftor has been shown to be a safe and effective, once-daily cystic fibrosis transmembrane conductance regulator (CFTR) modulator. Restoring normal CFTR function early in life has the potential to prevent manifestations of cystic fibrosis. We aimed to evaluate the safety, tolerability, efficacy, and pharmacokinetics of vanzacaftor-tezacaftor-deutivacaftor in children with cystic fibrosis aged 6-11 years.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!